Sensydia Raises More Than $6 Million for AI-Based Cardiac Pressure System
Sensydia, a clinical-stage medical technology company, has closed an oversubscribed initial financing of more than $6 million to advance its AI-based Cardiac Performance System (CPS™). The round was led by Colle Capital Partners, with substantial support from Orlando Health Ventures.
- Sensydia closed an oversubscribed initial financing of more than $6 million, led by Colle Capital Partners with support from Orlando Health Ventures.
- Funds are meant to carry the Cardiac Performance System (CPS™) through the ACOUSTIC-1 study to FDA authorization and support launch preparation.
- CPS uses acoustic and electrical signals and AI algorithms to assess pulmonary pressure without invasive catheterization.
- A Category III CPT® code, 1036T, took effect in July 2026 for non-invasive hemodynamic assessment.
- CPS has FDA Breakthrough Device designation but is not yet FDA-authorized.
What the funding will pay for
According to Sensydia, the proceeds will carry CPS through its ongoing ACOUSTIC-1 study to FDA authorization, while also supporting preparation for commercial launch. The company describes the round as an oversubscribed initial closing.
CPS is not yet FDA-authorized and is labeled for investigational use only. The company says the system has received FDA Breakthrough Device designation. Its regulatory history also includes FDA 510(k) clearance in 2018 for an algorithm for non-invasive measurement of ejection fraction.
How the Cardiac Performance System works
Sensydia says CPS is designed to give clinicians pulmonary pressure assessments in almost any setting, without the need for invasive catheterization. The system assesses cardiac function by acquiring acoustic and electrical signals and analyzing them with artificial intelligence algorithms.
The intended use is to help identify congestion and guide diagnosis and treatment in heart failure and pulmonary hypertension. Sensydia describes the platform as one that gives clinicians rapid, safe and accurate assessments of hemodynamic function in the office or clinic.
Colle Capital Partners founding partner Victoria Grace said Sensydia "built CPS on catheterization data, the clinical gold standard, at a scale few companies attempt."
A billing code is already in place
In July 2026, a new Category III CPT® code, 1036T, took effect for non-invasive hemodynamic assessment. According to the release, the code rests on three elements: passively acquired acoustic and electrical signals, augmentative algorithmic analysis, and physician review, interpretation and integration into clinical care. Sensydia says this is the same approach on which CPS is built.
Grace pointed to the code as one reason for the investor's confidence, saying that the team's discipline, "together with a CPT code already in place," gives Colle Capital "real confidence in this team."
What the backers and the company say
Anthony Arnold, CEO of Sensydia, said the company built CPS "to give clinicians objective pressure information in the office, where therapy decisions are made." He added that the company is focused on bringing CPS to market rapidly to help patients with heart failure.
Bill Hawkins, retired Chairman and CEO of Medtronic and an advisor to Sensydia, said the company "has the makings" of a category-creating medical technology business, offering "a new way to bring pressure information to the point of care."
Colle Capital Partners describes itself as a global, early-stage technology venture fund. Orlando Health Ventures invests in medtech, biotech and services companies that could improve patient outcomes or workflows across the health system.
What it means
For now, CPS remains an investigational device. The funding gives Sensydia resources to complete ACOUSTIC-1 and pursue FDA authorization. If authorization comes, the system would target office and clinic settings where cardiologists make therapy decisions for patients with heart failure. Sensydia notes that its release contains forward-looking statements and that actual results may differ materially.
